NASDAQ:MDCO - The Medicines Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$31.84 -0.13 (-0.41 %)
(As of 05/21/2018 01:07 PM ET)
Previous Close$31.97
Today's Range$31.74 - $32.35
52-Week Range$24.45 - $43.86
Volume8,410 shs
Average Volume1.25 million shs
Market Capitalization$2.35 billion
P/E Ratio-3.79
Dividend YieldN/A
Beta0.67

About The Medicines (NASDAQ:MDCO)

The Medicines logoThe Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Debt-to-Equity Ratio9.70
Current Ratio2.56
Quick Ratio2.52

Price-To-Earnings

Trailing P/E Ratio-3.79
Forward P/E Ratio-9.07
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.79 million
Price / Sales52.33
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book93.65

Profitability

EPS (Most Recent Fiscal Year)($8.40)
Net Income$-708,370,000.00
Net Margins-1,109.21%
Return on Equity-609.97%
Return on Assets-66.38%

Miscellaneous

Employees170
Outstanding Shares73,610,000

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its quarterly earnings data on Wednesday, April, 25th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.03. The business earned $7.71 million during the quarter, compared to analyst estimates of $9.21 million. The Medicines had a negative return on equity of 609.97% and a negative net margin of 1,109.21%. The company's revenue was down 55.8% compared to the same quarter last year. During the same period last year, the company posted ($1.05) EPS. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

7 equities research analysts have issued 12 month price objectives for The Medicines' shares. Their forecasts range from $40.00 to $85.00. On average, they expect The Medicines' stock price to reach $52.00 in the next year. View Analyst Ratings for The Medicines.

What are Wall Street analysts saying about The Medicines stock?

Here are some recent quotes from research analysts about The Medicines stock:
  • 1. According to Zacks Investment Research, "The Medicines Co. reported wider-than-expected loss in the first quarter of 2018 with revenues missing estimates. The company’s pipeline boasts a potential blockbuster candidate, inclisiran, being developed for hypercholesterolemia. Moreover, the company implemented a workforce lay-off last year for better alignment of its cost and structure. We are also encouraged by The Medicines Co.’s regular divestiture of non-core products. This would help optimize its capital structure and enhance its liquidity position. However, with Angiomax sales eroding due to presence of generics, the company’s ability to successfully develop and bring in new products to the market is highly important for growth. Any regulatory setback would weigh heavily on the stock. Shares of the company have underperformed the industry in a year’s time." (5/2/2018)
  • 2. Chardan Capital analysts commented, "We found particularly notable: (1) MDCO completing recruitment in just 11 weeks for its 1500-patient ORION-11 pivotal phase III trial of siRNA- based PSCK9 synthesis inhibitor inclisiran (partnered with Alnylam, Buy) and may thus have its first top-line pivotal results in 3Q19, (2) the confirmation commercial scale manufacturing for inclisiran has been achieved, and (3) new inclisiran efficacy data in HoFH to us suggesting efficacy beyond mAb PCSK9 inhibitors. With inclisiran to us having clear momentum towards 2H19E pivotal data and what we expect will be $4.7 billion in 2030E peak sales, we make MDCO a Chardan Top Pick for 2018." (1/24/2018)

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Dr. Fredric N. Eshelman, Exec. Chairman (Age 69)
  • Dr. Clive A. Meanwell, CEO & Director (Age 60)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 53)
  • Mr. William B. O'Connor, Special Advisor to the Chief Exec. Officer (Age 59)

Has The Medicines been receiving favorable news coverage?

News coverage about MDCO stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Medicines earned a media sentiment score of 0.08 on Accern's scale. They also gave press coverage about the company an impact score of 46.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are The Medicines' major shareholders?

The Medicines' stock is owned by many different of retail and institutional investors. Top institutional investors include PointState Capital LP (5.03%), Westfield Capital Management Co. LP (4.12%), Iridian Asset Management LLC CT (2.93%), Franklin Resources Inc. (2.66%), venBio Select Advisor LLC (2.22%) and Pinnacle Associates Ltd. (1.50%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Hiroaki Shigeta, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.

Which institutional investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including University of Notre Dame DU Lac, Franklin Resources Inc., Elk Creek Partners LLC, Pinnacle Associates Ltd., Iridian Asset Management LLC CT, Guggenheim Capital LLC, American International Group Inc. and Teacher Retirement System of Texas. Company insiders that have sold The Medicines company stock in the last year include Armin M Kessler, Clive Meanwell and William Crouse. View Insider Buying and Selling for The Medicines.

Which institutional investors are buying The Medicines stock?

MDCO stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, venBio Select Advisor LLC, Antipodean Advisors LLC, Westfield Capital Management Co. LP, A.R.T. Advisors LLC, Eversept Partners LLC, Wexford Capital LP and New York State Common Retirement Fund. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $31.84.

How big of a company is The Medicines?

The Medicines has a market capitalization of $2.35 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. The Medicines employs 170 workers across the globe.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (MDCO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

The Medicines (NASDAQ:MDCO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for The Medicines in the last 12 months. Their average twelve-month price target is $52.00, suggesting that the stock has a possible upside of 63.32%. The high price target for MDCO is $85.00 and the low price target for MDCO is $40.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.78
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $52.00$52.00$53.6667$55.25
Price Target Upside: 63.32% upside58.34% upside76.13% upside70.58% upside

The Medicines (NASDAQ:MDCO) Consensus Price Target History

Price Target History for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ:MDCO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018OppenheimerReiterated RatingBuyLowView Rating Details
2/23/2018Jefferies GroupReiterated RatingBuy$47.00LowView Rating Details
1/24/2018Chardan CapitalReiterated RatingBuy$85.00HighView Rating Details
1/24/2018JPMorgan ChaseReiterated RatingOverweight ➝ Overweight$45.00HighView Rating Details
1/22/2018CitigroupUpgradeNeutral ➝ Buy$40.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/AView Rating Details
8/10/2017CowenReiterated RatingBuy$61.00 ➝ $54.00HighView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 ➝ $50.00N/AView Rating Details
7/12/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

The Medicines (NASDAQ:MDCO) Earnings History and Estimates Chart

Earnings by Quarter for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ:MDCO) Earnings Estimates

2018 EPS Consensus Estimate: ($2.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.02)($0.64)($0.85)
Q2 20183($0.94)($0.63)($0.83)
Q3 20183($0.78)($0.44)($0.59)
Q4 20183($0.72)($0.45)($0.59)

The Medicines (NASDAQ MDCO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.64)N/AView Earnings Details
4/25/2018Q1 2018($0.80)($0.77)$9.21 million$7.71 millionViewN/AView Earnings Details
2/21/2018Q4 2017($1.48)($2.19)$20.71 million$8.60 millionViewListenView Earnings Details
10/25/2017Q3 2017($1.37)($0.42)$26.06 million$16.87 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.29)($5.52)$29.64 million$18.74 millionViewListenView Earnings Details
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
10/27/2010Q3 2010$0.24$0.40ViewN/AView Earnings Details
7/28/2010Q2 2010$0.23$0.29ViewN/AView Earnings Details
4/28/2010Q1 2010$0.13$0.19ViewN/AView Earnings Details
2/15/2010Q4 2009($1.40)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.05)($0.06)ViewN/AView Earnings Details
7/29/2009Q2 2009$0.05$0.07ViewN/AView Earnings Details
4/29/2009Q1 2009($0.03)($0.04)ViewN/AView Earnings Details
2/18/2009Q4 2008$0.03($0.08)ViewN/AView Earnings Details
7/23/2008Q2 2008$0.07$0.08ViewN/AView Earnings Details
4/23/2008Q1 2008$0.06$0.09ViewN/AView Earnings Details
2/13/2008Q4 2007$0.02$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

The Medicines (NASDAQ:MDCO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

The Medicines (NASDAQ MDCO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.22%
Insider Trading History for The Medicines (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ MDCO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Armin M. KesslerDirectorSell20,000$28.71$574,200.00View SEC Filing  
3/21/2018William CrouseDirectorSell7,500$32.26$241,950.0060,633View SEC Filing  
12/15/2017Clive MeanwellCEOSell136,250$27.24$3,711,450.00587,652View SEC Filing  
12/8/2017Fredric N EshelmanInsiderBuy200,000$26.56$5,312,000.001,028,383View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy170,000$30.03$5,105,100.006,663View SEC Filing  
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.6030,935View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.0033,670View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40641,106View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00347,791View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00339,168View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00358,790View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.5023,547View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.5033,670View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.0020,800View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.0053,970View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00348,790View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.0053,970View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.0049,817View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00300,000View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00144,930View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.0027,720View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.0099,805View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28324,905View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.2599,805View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.0038,970View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.0024,732View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.0827,870View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.6631,029View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.0525,058View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.0025,058View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77297,773View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56297,773View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.0029,849View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00118,405View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00307,773View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00317,773View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.0051,906View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

The Medicines (NASDAQ MDCO) News Headlines

Source:
DateHeadline
Meet The Entrepreneurs Pioneering The "Clean Medicine" MovementMeet The Entrepreneurs Pioneering The "Clean Medicine" Movement
www.forbes.com - May 18 at 4:57 PM
Drug Prices Drive Many Americans to Black Market for MedicinesDrug Prices Drive Many Americans to Black Market for Medicines
www.bloomberg.com - May 18 at 9:59 AM
Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of ...Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of ...
www.prnewswire.com - May 18 at 9:59 AM
Blueprint Medicines (BPMC) Announces Data Presentations at Upcoming ASCO and EHA MeetingsBlueprint Medicines (BPMC) Announces Data Presentations at Upcoming ASCO and EHA Meetings
www.streetinsider.com - May 17 at 5:00 PM
Pharmaceutical Price Controls Will Not Improve Health Care Outcomes in IllinoisPharmaceutical Price Controls Will Not Improve Health Care Outcomes in Illinois
www.forbes.com - May 17 at 5:00 PM
Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid ...Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid ...
www.prnewswire.com - May 17 at 5:00 PM
Medicines (MDCO) Raised to "Sell" at BidaskClubMedicines (MDCO) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - May 16 at 11:04 AM
Homology Medicines Reports First Quarter 2018 Financial ResultsHomology Medicines Reports First Quarter 2018 Financial Results
www.prnewswire.com - May 14 at 4:57 PM
Trump Outlines Plan to Lower Drug PricesTrump Outlines Plan to Lower Drug Prices
www.nytimes.com - May 11 at 5:21 PM
Homology Medicines to Present at Bank of America Merrill Lynch Healthcare ConferenceHomology Medicines to Present at Bank of America Merrill Lynch Healthcare Conference
www.prnewswire.com - May 10 at 9:01 AM
Patients sue Gilead, saying drug company intentionally delayed safer HIV medicinePatients sue Gilead, saying drug company intentionally delayed safer HIV medicine
www.latimes.com - May 9 at 8:56 AM
Medicines (MDCO) Rating Increased to Sell at BidaskClubMedicines (MDCO) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - May 9 at 6:36 AM
argenx reports first quarter 2018 financial results and provides business updateargenx reports first quarter 2018 financial results and provides business update
feeds.benzinga.com - May 9 at 3:13 AM
Medicines (MDCO) and Its Peers Financial ComparisonMedicines (MDCO) and Its Peers Financial Comparison
www.americanbankingnews.com - May 8 at 5:19 PM
The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of ...The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of ...
www.businesswire.com - May 7 at 5:08 PM
Medicines (MDCO) Receives Consensus Rating of "Buy" from AnalystsMedicines (MDCO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 7 at 1:49 PM
Medicines (MDCO) Expected to Post Quarterly Sales of $7.58 MillionMedicines (MDCO) Expected to Post Quarterly Sales of $7.58 Million
www.americanbankingnews.com - May 7 at 2:52 AM
-$0.64 Earnings Per Share Expected for Medicines (MDCO) This Quarter-$0.64 Earnings Per Share Expected for Medicines (MDCO) This Quarter
www.americanbankingnews.com - May 5 at 3:11 PM
Head-To-Head Review: Medicines (MDCO) & Its RivalsHead-To-Head Review: Medicines (MDCO) & Its Rivals
www.americanbankingnews.com - May 5 at 11:22 AM
European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo Plus Yervoy ...European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo Plus Yervoy ...
www.businesswire.com - May 3 at 4:58 PM
Blog Exposure - Ironwood to Separate Its Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal BusinessBlog Exposure - Ironwood to Separate Its Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business
finance.yahoo.com - May 3 at 8:55 AM
Medicines (MDCO) Upgraded at Zacks Investment ResearchMedicines (MDCO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 2 at 11:47 AM
The Medicines Patent Pool Adds New Suppliers from South Africa and South Korea to its Growing Generic ...The Medicines Patent Pool Adds New Suppliers from South Africa and South Korea to its Growing Generic ...
www.prnewswire.com - May 2 at 8:46 AM
BRIEF-Blueprint Medicines Q1 Loss Per Share $1.29BRIEF-Blueprint Medicines Q1 Loss Per Share $1.29
www.reuters.com - May 2 at 8:46 AM
Blueprint Medicines Reports First Quarter 2018 Financial ResultsBlueprint Medicines Reports First Quarter 2018 Financial Results
www.prnewswire.com - May 2 at 8:46 AM
Blueprint Medicines  misses by $0.16, misses on revenueBlueprint Medicines  misses by $0.16, misses on revenue
seekingalpha.com - May 2 at 7:09 AM
BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of InfluenzaBRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza
www.reuters.com - May 1 at 8:44 AM
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the ...Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the ...
globenewswire.com - April 30 at 5:01 PM
BRIEF-Medicines Co Says CEO Clive A. Meanwells 2017 Total Compensation Was $7.6 MillionBRIEF-Medicines Co Says CEO Clive A. Meanwell's 2017 Total Compensation Was $7.6 Million
www.reuters.com - April 30 at 5:01 PM
Homology Medicines Announces Upcoming Presentations on its Genetic Medicines Platform at the American Society of ...Homology Medicines Announces Upcoming Presentations on its Genetic Medicines Platform at the American Society of ...
www.prnewswire.com - April 30 at 5:01 PM
AB Science reports today its annual financials as of 31 December 2017 and provides an update on its activitiesAB Science reports today its annual financials as of 31 December 2017 and provides an update on its activities
feeds.benzinga.com - April 30 at 2:34 PM
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual MeetingEditas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
feeds.benzinga.com - April 30 at 2:34 PM
The Medicines Company Presents New Data at the National Lipid Association Scientific SessionsThe Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
finance.yahoo.com - April 30 at 9:59 AM
Medicines Companys (MDCO) Q1 Loss Widens, Revenues Tank Y/YMedicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y
www.nasdaq.com - April 27 at 4:54 PM
Report Offers Hope, Outlines 537 New Drugs In Development For Neurological DisordersReport Offers Hope, Outlines 537 New Drugs In Development For Neurological Disorders
www.forbes.com - April 27 at 4:54 PM
Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/YMedicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y
finance.yahoo.com - April 27 at 4:54 PM
[$$] UK ratifies European patent court agreement[$$] UK ratifies European patent court agreement
finance.yahoo.com - April 26 at 4:55 PM
Edited Transcript of MDCO earnings conference call or presentation 25-Apr-18 12:30pm GMTEdited Transcript of MDCO earnings conference call or presentation 25-Apr-18 12:30pm GMT
finance.yahoo.com - April 26 at 4:55 PM
Proteus Digital Health® Announces Digital Medicines Pipeline Development and Expansion into OncologyProteus Digital Health® Announces Digital Medicines Pipeline Development and Expansion into Oncology
www.businesswire.com - April 25 at 4:57 PM
The Medicines (MDCO) Q1 2018 Results - Earnings Call TranscriptThe Medicines (MDCO) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 25 at 4:57 PM
Medicines (MDCO) Announces  Earnings ResultsMedicines (MDCO) Announces Earnings Results
www.americanbankingnews.com - April 25 at 1:40 PM
BRIEF-The Medicines Co Reports Q1 GAAP Loss Per Share $1.14 From Continuing OperationsBRIEF-The Medicines Co Reports Q1 GAAP Loss Per Share $1.14 From Continuing Operations
www.reuters.com - April 25 at 9:13 AM
Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018
www.prnewswire.com - April 25 at 9:13 AM
The Medicines Company Reports First-Quarter 2018 ResultsThe Medicines Company Reports First-Quarter 2018 Results
finance.yahoo.com - April 25 at 9:13 AM
Medicines Co.: 1Q Earnings SnapshotMedicines Co.: 1Q Earnings Snapshot
finance.yahoo.com - April 25 at 9:13 AM
Medicines (MDCO) Cut to Strong Sell at BidaskClubMedicines (MDCO) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM
This App Helps Donate Leftover Drugs To People Who Struggle To Afford Health CareThis App Helps Donate Leftover Drugs To People Who Struggle To Afford Health Care
www.huffingtonpost.com - April 24 at 8:51 AM
BRIEF-Revolution Medicines Raises $56 Mln Series B FinancingBRIEF-Revolution Medicines Raises $56 Mln Series B Financing
www.reuters.com - April 24 at 8:51 AM
European Medicines Agency Validates Type II Variation for Mercks KEYTRUDA® (pembrolizumab) in Combination ...European Medicines Agency Validates Type II Variation for Merck's KEYTRUDA® (pembrolizumab) in Combination ...
www.businesswire.com - April 23 at 4:51 PM
BRIEF-China National Accord Medicines Posts 7.4 Pct Rise In Q1 Net ProfitBRIEF-China National Accord Medicines Posts 7.4 Pct Rise In Q1 Net Profit
www.reuters.com - April 23 at 9:22 AM

SEC Filings

The Medicines (NASDAQ:MDCO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

The Medicines (NASDAQ:MDCO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

The Medicines (NASDAQ MDCO) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.